Navigation Links
OxThera Raises Capital for Further Clinical Development of Oxabact(R)
Date:9/19/2012

STOCKHOLM, September 19, 2012 /PRNewswire/ --

OxThera AB has successfully raised MSEK 39 in a rights issue. The proceeds from the financing will enable OxThera to complete a new clinical study to confirm the positive effects of treatment with Oxabact® previously seen in patients with Primary Hyperoxaluria, a debilitating medical condition for which there is no effective treatment today.

"We appreciate the continued support from our shareholders, including HealthCap, Industrifonden and Q-Med[1], as well as their strong belief in Oxabact®", says Elisabeth Lindner, CEO of OxThera. "Our mapping of OxThera's previous scientific and clinical findings has resulted in an improved medical product that will support a regulatory filing for a confirmatory clinical trial later this year." Elisabeth Lindner continues.

OxThera holds proprietary rights to pharmaceutical preparations and their use for treatment of hyperoxaluria. Oxabact® is an oral product composed of highly concentrated freeze-dried live bacteria (Oxalobacter formigenes), administered in capsules. The drug is designed for delivery in the lower part of the small intestine, where enteric elimination of endogenous oxalate is initiated. OxThera is currently discussing a complete Oxabact® clinical development plan with regulatory agencies in the EU and in the US for the treatment of patients suffering from Primary Hyperoxaluria.

About primary hyperoxaluria

Primary hyperoxaluriais a rare inborn autosomal genetic disorder leading to markedly elevated levels of endogenous oxalate in plasma and urine. High levels of urinary oxalate cause kidney damage, including kidney stone formation and/or calcification of the kidney. If left untreated, the disease can cause kidney failure and premature death. There is a high medical need for effective treatments of Primary Hyperoxaluria. Curren
'/>"/>

SOURCE OxThera
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Avaxia Biologics, Inc. Raises $2.2 Million in First Closing of Series A Financing to Advance Oral Antibodies for Inflammatory Bowel Disease
2. Cowen Healthcare Royalty Partners Raises $1 Billion
3. Biotech Firm Spun Off from Childrens Hospital Raises $7 Million to Advance Magnetic-Based Vascular Treatment
4. Cerecor Raises $22 Million Series A Financing
5. Sangart Raises Additional $50M Series G Funding Following Interim Safety Analysis Of Phase 2b Study Of MP4OX In Severe Trauma Patients With Hemorrhagic Shock
6. Rhythm Raises $25M in Series B Financing for Diabetes and Obesity Therapeutics
7. Juventas Therapeutics Raises $22.2 Million Series B Financing
8. Relmada Therapeutics Raises $3.0 Million In Initial Closing Of Series A Financing
9. Safeway Raises Over $9 Million to Fund Prostate Cancer Research
10. MiMedx Group Raises over $4.9 Million through the Exercise of Callable Warrants
11. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... 2014 US demand to rise 3.9% annually ... is forecast to rise 3.9 percent per year to ... projected to increase 1.3 percent per year to 1.5 ... in construction expenditures will support demand for biocides in ... growth in consumer spending and manufacturing output will support ...
(Date:9/22/2014)... Invisible Sentinel Inc., a life-sciences company ... beverage industries, announced today that its first-in-class Veriflow® ... agreement by Enartis, a global provider of specialty ... Group company headquartered in Trecate, Italy, will distribute ... global markets for their own in-winery use in ...
(Date:9/22/2014)... LONDON , September 22, 2014 ... ended on a mixed note as the Dow Jones ... NASDAQ Composite closed at 4,579.79, down 0.30%. The S&P ... the trading session, six out of ten sectors finished ... Sector Index ended the day at 751.48, up 0.10%, ...
(Date:9/21/2014)... first time, scientists have discovered how to produce ultra-thin ... stiffness greater than that of today,s strongest nanotubes and ... team led by John V. Badding, a professor of ... the 21 September 2014 issue of the journal ... view, our discovery is intriguing because the threads we ...
Breaking Biology Technology:US Biocides Market 2US Biocides Market 3Invisible Sentinel's Test for Wine-Spoilage Microbe to be Distributed by Enartis in Multiple Markets Globally 2Invisible Sentinel's Test for Wine-Spoilage Microbe to be Distributed by Enartis in Multiple Markets Globally 3Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 2Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 3Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 4Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 5Smallest possible diamonds form ultra-thin nanothreads 2Smallest possible diamonds form ultra-thin nanothreads 3Smallest possible diamonds form ultra-thin nanothreads 4
... - From less than 1 million to 600 ... growth in the past 10 years. , ,From the ... job, providing better tools for finding, filtering and presenting ... decade on the Web and also looking forward to ...
... Madison, Wis. - Stratatech Corporation , a UW ... from the National Institute on Aging, for the development of ... wounds such as diabetic, venous stasis and pressure ulcers, which ... estimated that in the United States alone, millions of people ...
... Madison, Wis. Pierce Biotechnology , a ... BioSurfaces of Madison, Wis., to distribute GenTel's trademarked ... use of GenTel technology in developing new protein arrays ... specifically designed for protein-array applications, including the profiling of ...
Cached Biology Technology:Internet Scout celebrates 10 years on web, eyes new project launch 2
(Date:9/22/2014)... New Haven, Conn. Yale University researchers are studying ... pulmonary fibrosis, a respiratory disease in which scars develop ... treatment uses a microRNA mimic, miR-29, which is delivered ... only blocked pulmonary fibrosis, it reversed fibrosis after ... in the journal EMBO Molecular Medicine . , ...
(Date:9/22/2014)... molecular cog in a plant,s biological clock one ... on temperature. , Transcription factors, or genetic switches, drive ... such as light, rain, soil quality, or even animals ... has isolated one, called FBH1, that reacts to temperature ... while in keeping it on a consistent track. , ...
(Date:9/22/2014)... of the fires captured in this image burn in Khabarovsk ... Okhotsk. Dozens of red hotspots, accompanied by plumes of smoke ... grey, blows to the east towards the Sea of Okhotsk. ... of this area, swampy forest inhabit the central depression, and ... While large wildfires are common in Russia in the summer, ...
Breaking Biology News(10 mins):Reversing the effects of pulmonary fibrosis 2Genetic switch regulates a plant's internal clock based on temperature 2
... Recognizes Leadership in Technology and Innovation in Global ... LMT ) has been named the ... Frost and Sullivan, recognizing the Corporation,s leadership in ... of customers. Frost and Sullivan based the award ...
... The Centre for Genomic Regulation (CRG) in Barcelona, Spain ... by Genomatix Software GmbH. , GGA comprises purpose built ... software providing a complete solution for the analysis of ... genome. "In regards to the machine, I love ...
... 4, 2009 The incidence of pneumothorax (PTX), or collapsed ... has been reported to range from 13 50 percent, ... In people, PTX is reported to be the most preventable ... ultrasound has been infrequently used as a non-invasive, point-of-care imaging ...
Cached Biology News:Lockheed Martin Named Biometrics 'Company of the Year' by Frost and Sullivan 2CRG buys Genomatix' Next Generation Sequencing analysis solution 2Novel veterinary procedure detecting life-threatening injuries touted 2
Use the DUALmembrane kit 3 to carry out DUALmembrane interaction analysis and cDNA library screening to characterize interactions between integral membrane proteins and to identify novel interaction ...
Human Serum FDA Licensed US Donor Centers Sterile / Non-sterile: Sterile Filtered to 0.2 micron Information: Extensive Viral Testing ...
Normal human AB serum, pooled...
Human alpha-1-antitrypsin. No cross-reactivity with alpha-1-acid glycoprotein, serum albumin or other serum proteins....
Biology Products: